Suara.com – British scientists have developed a vaccine malaria has been shown to be effective in infant trials. The R21 / Matrix-M vaccine shot demonstrated an efficacy rate of 77 percent in a year-long trial involving 450 children in Burkina Faso, South Africa.
The Oxford University team led by Adrian Hill, one of the researchers behind the AstraZeneca vaccine for Covid-19 The Sun, is planning to run a final phase trial for malaria vaccine.
The final phase of the trial will involve 4,800 children aged 5 months and 3 years in 4 African countries. Professor Hill, director of the Jenner Institute Oxford, Professor Hill, director of the Jenner Institute Oxford, admits that he has high hopes for this malaria vaccine.
The vaccine will be the first to realize the World Health Organization’s goal of getting a malaria vaccine, which has an efficacy rate of at least 75 percent.
Also Read:
New Evidence, Humans Can Spread Corona Covid-19 Virus to Cats!
The only licensed malarian vaccine in the world is Mosquirix. The malarian vaccine was developed by Glaxo-SmithKline, but is only partially effective, or about 30 percent.
It should be understood that malaria is a disease of mosquito which infects millions of people each year, mostly children in parts of Africa.
Malaria is a serious and dangerous disease caused by parasites of the plasmodium type. This parasite is transmitted through mosquito bites, especially the anopheles mosquito.
When the Anopheles mosquito becomes infected with the Plasmodium parasite and bites you, it can be transmitted and released into your bloodstream.
Parasites will develop in the liver and will start attacking red blood cells within a few days. When you are infected, symptoms will start to appear after 10 days to 4 weeks.
Also Read:
Mount Everest Starts Contaminated by Corona Virus
But reported from Hellosehat, symptoms can also appear 7 days after infection. The most common symptoms include fever, headache and vomiting.
– .
